Biocardia Inc (BCDA)

NASDAQ
1.420
-0.050(-3.40%)
  • Volume:
    51,912
  • Day's Range:
    1.340 - 1.540
  • 52 wk Range:
    1.100 - 4.540

BCDA Overview

Prev. Close
1.47
Day's Range
1.34-1.54
Revenue
1.03M
Open
1.5
52 wk Range
1.1-4.54
EPS
-0.76
Volume
51,912
Market Cap
25.65M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
686,216
P/E Ratio
-
Beta
1.44
1-Year Change
-68.79%
Shares Outstanding
17,446,265
Next Earnings Date
Aug 11, 2022
What is your sentiment on Biocardia?
or
Market is currently closed. Voting is open during market hours.

Biocardia Inc Company Profile

Biocardia Inc Company Profile

Employees
32

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • Think again!
    0
    • I think this stock is no more
      2
      • Accomplished Biotech Executive Krisztina Zsebo, Ph.D. Joins BioCardia’s Board of Directors
        0
        • So after gap closing you should start next week BCDA
          0
          • Gap is closed
            0
            • https://dawsonjames.com/wp-content/uploads/2020/05/BCDA.update.5.5.20.pdf
              0
              • PT of $24 and a buy rating from 22 analysts
                0
              • You said the price target was $11, now its $24!? Wow - that would be a beautiful thing to see.
                1
              • This article is 8 months old Yael.
                0
            • Hey Yael - what’s happening here?
              0
              • Targetprice for BCDA from Allianz 11$
                0
                • $400$3$52$90210$0$Fish
                  0
                  • Bravoo
                    0
                • 7.55
                  0